Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Background: [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary...

Full description

Bibliographic Details
Main Authors: Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka, Alexander R. Haug, Marcus Hacker, Markus Hartenbach, Sazan Rasul
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Current Oncology
Subjects:
PSMA
prostate cancer
mCRPC
renal scintigraphy
salivary scintigraphy
Online Access:https://www.mdpi.com/1718-7729/28/5/315

Similar Items

Similar Items